Reaction
Arteriovenous Malformation reporting signals
As of the last recalculation, Arteriovenous Malformation appears in 904 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is ADO-TRASTUZUMAB EMTANSINE (PRR 58.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ado-Trastuzumab Emtansine | 21 | 58.7 | 58.8 |
| Epoprostenol | 13 | 23.2 | 23.2 |
| Dexamethasone Sodium Phosphate | 10 | 22.9 | 22.9 |
| Dabigatran Etexilate | 50 | 15.6 | 15.6 |
| Dabigatran Etexilate Mesylate | 45 | 15.0 | 15.0 |
| Selexipag | 15 | 13.6 | 13.6 |
| Macitentan | 36 | 12.4 | 12.4 |
| Apixaban | 32 | 11.4 | 11.4 |
| Riociguat | 15 | 10.8 | 10.8 |
| Ambrisentan | 36 | 6.9 | 6.9 |